Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)

T-cell Lymphoma Clinical Trial

Official title:

STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01553786
• Other study ID #: REVAIL
• Status: Completed
• Phase: Phase 2
• Start date: November 2011
• Est. completion date: March 21, 2019

Study information

• Verified date: July 2021
• Source: The Lymphoma Academic Research Organisation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate the efficacy of lenalidomide associated with CHOP as measured by complete response rate at the end of treatment. Approximately 80 patients aged between 60 and 80 years will be included, to have 70 evaluable patients. The treatment consists of two phases of four 3-weeks cycles: induction phase and consolidation phase, for a total treatment duration of 24 weeks. Each cycle will be broken down as follows: chemotherapy will be administered in the hospital on day 1, prednisone is continued for 5 days and lenalidomide is taken for 14 days. Patients will be followed for at least 18 months after inclusion of the last patient.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: March 21, 2019
• Est. primary completion date: March 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with histologically proven T-cell angioimmunoblastic lymphoma (AITL)
• Age from 60 to 80 years.
• Eastern Cooperative Oncology Group performance status 0 to 2.
• No previous therapy (except corticosteroids providing they have been initiated less than 15 days before inclusion).
• Spontaneous life expectancy > 1 month.
• Written informed consent. The Lenalidomide Information Sheet (in appendix N of the protocol) will be given to each patient receiving lenalidomide study therapy. The patient must read this document prior to starting lenalidomide study treatment and each time they receive a new supply of study drug.
• Male patients must:
• Agree to use a condom during sexual contact with a FCBP, even if they have had a vasectomy, throughout study drug therapy, during any dose interruption and after cessation of study therapy.
• Agree to not give semen or sperm during study drug therapy and for a period after end of study drug therapy.
• All patients must:
• Have an understanding that the study drug could have a potential teratogenicity.
• Agree to abstain from donating blood while taking study drug therapy and following discontinuation of study drug therapy.
• Agree not to share study medication with another person.
• Be counselled about pregnancy precautions and risks of foetal exposure.

Exclusion Criteria:

• Others categories of T-cell lymphoma.
• Central nervous system involvement by lymphoma.
• Any previous therapy for lymphoma except short-term corticosteroids (maximum 10 days) before inclusion.
• Contra-indication to any drug included in the CHOP regimen.
• Serious medical or psychiatric illness likely to interfere with participation in this clinical study (according to the investigator's decision).
• Active bacterial, viral or fungal infection, in particular active hepatitis B or C and HIV positive serological test.
• Impaired renal function (Creatinine clearance <50 ml/min (as calculated by the Cockcroft-Gault formula)) or impaired liver function tests (total bilirubin level > 30 µmol/L, transaminases > 2.5 upper normal limits) unless they are related to the lymphoma.
• Poor bone marrow reserve as defined by neutrophils < 1.0 x 109/L or platelets < 100 x 109/L, unless related to bone marrow infiltration.
• Any history of malignancy, other than that treated in this research, unless the patient has remained free of the disease for over 5 years.
• Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.
• Hypersensitivity to the active substance or to any of the excipients.
• Pregnant and lactating woman
• Females of Childbearing potential (FCBP*) according to the Pregnancy Prevention Plan in appendix L of the protocol)
• The Pregnancy Prevention Plan defines a female of childbearing potential as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, T-Cell
• T-cell Lymphoma

Intervention

Drug:
• Lenalidomide
Lenalidomide

Locations

Country	Name	City	State
Belgium	Université Catholique de Louvain Saint Luc	Bruxelles
Belgium	Universitair Ziekenhuis Gent	Gent
Belgium	Université Catholique de Louvain Mont Godinne	Yvoir
France	CHU d'Amiens - Hôpital Sud	Amiens
France	CHU Angers	Angers
France	CH d'Avignon - Hôpital Henri Duffaut	Avignon
France	CHU Jean Minjoz	Besançon
France	Institut Bergonié	Bordeaux
France	Polyclinique Bordeaux Nord Aquitaine	Bordeaux
France	Centre hospitalier Chalon sur Saone William Morey	Châlon sur saône
France	CHU Estaing	Clermont Ferrand
France	CH Sud Francilien de Corbeil	Corbeil Essonnes
France	Hôpital Henri Mondor	Créteil
France	CHU de Dijon	Dijon
France	CHU de Grenoble	Grenoble
France	CH Départemental	La roche sur Yon
France	CHRU de Lille	Lille
France	Institut Paoli Calmette	Marseille
France	Centre Hospitalier de Meaux	Meaux
France	CHU Saint-Eloi	Montpellier
France	CHU Hôtel Dieu	Nantes
France	Hôpital Necker	Paris
France	Hôpital Saint Louis	Paris
France	Centre Francois Magendie	Pessac
France	CHU Lyon Sud	Pierre Bénite
France	Centre Hospitalier de la Région d'Annecy	Pringy
France	CHU Robert Debré	Reims
France	CHU Pontchaillou	Rennes
France	Centre Henri Becquerel	Rouen
France	CHU Brabois	Vandoeuvre les Nancy

Sponsors (1)

Lead Sponsor	Collaborator
The Lymphoma Academic Research Organisation

Countries where clinical trial is conducted

Belgium,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete response rate		maximum 60 days after last study drug intake